Your browser doesn't support javascript.
loading
Is BRCA2 involved in early onset colorectal cancer risk?
Gay-Bellile, Mathilde; Privat, Maud; Martins, Alexandra; Caputo, Sandrine M; Pebrel-Richard, Céline; Cavaillé, Mathias; Viala, Sandrine; Corsini, Carole; Rodrigues, Michael; Barnich, Nicolas; Bidet, Yannick; Uhrhammer, Nancy; Bignon, Yves-Jean.
Affiliation
  • Gay-Bellile M; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, France.
  • Privat M; Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
  • Martins A; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, France.
  • Caputo SM; Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
  • Pebrel-Richard C; INSERM U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, UNIROUEN, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Cavaillé M; Institut Curie, Service de Génétique, Paris, France.
  • Viala S; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, France.
  • Corsini C; Service de Cytogénétique Médicale, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Rodrigues M; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, France.
  • Barnich N; Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
  • Bidet Y; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, France.
  • Uhrhammer N; Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
  • Bignon YJ; Département de Génétique Médicale, unité d'oncogénétique clinique, Hôpital Arnaud de Villeneuve, CHRU de Montpellier, France.
Clin Genet ; 97(4): 668-669, 2020 04.
Article in En | MEDLINE | ID: mdl-31875949
ABSTRACT
A, Closed symbols indicate patients affected with cancer. Open symbols indicate healthy individuals. The type of cancer and age at presentation are given in brackets. Blue circle represents c.4471_4474del variant and red circle represents the c.9648 + 1G > A. B, RNA was extracted from blood of patient III-3 and his sisters III-1 and III-4. RT-PCR analysis was performed with primers mapping to exons 25 and 27, and PCR products were separated by Bioanalyzer electrophoresis. The sizes of the DNA marker (M) are indicated to the left. LM, lower marker; UM, upper marker. C, Each RT-PCR product from patient III-3 was gel-purified and analyzed by Sanger sequencing. The 297-bp band corresponds to the reference BRCA2 transcript and the 150-bp band corresponds to a BRCA2 transcript lacking exon 26.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Genetic Predisposition to Disease / BRCA2 Protein Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Journal: Clin Genet Year: 2020 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Genetic Predisposition to Disease / BRCA2 Protein Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Journal: Clin Genet Year: 2020 Document type: Article Affiliation country: France